319 related articles for article (PubMed ID: 24650154)
21. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
[TBL] [Abstract][Full Text] [Related]
22. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
Abdelalem Aziz Ahmed M
F1000Res; 2019; 8():2078. PubMed ID: 32431802
[No Abstract] [Full Text] [Related]
23. Safinamide: a new hope for Parkinson's disease?
Teixeira FG; Gago MF; Marques P; Moreira PS; Magalhães R; Sousa N; Salgado AJ
Drug Discov Today; 2018 Mar; 23(3):736-744. PubMed ID: 29339106
[TBL] [Abstract][Full Text] [Related]
24. Safinamide: A Review in Parkinson's Disease.
Blair HA; Dhillon S
CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399
[TBL] [Abstract][Full Text] [Related]
25. Safinamide (Newron Pharmaceuticals).
Chazot PL
Curr Opin Investig Drugs; 2001 Jun; 2(6):809-13. PubMed ID: 11572661
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
Kurihara K; Mishima T; Fujioka S; Tsuboi Y
Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
[TBL] [Abstract][Full Text] [Related]
27. Safinamide (Xadago) for Parkinson's disease.
Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847
[No Abstract] [Full Text] [Related]
28. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
[TBL] [Abstract][Full Text] [Related]
29. 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.
Chung JY; Lee JW; Ryu CH; Min HK; Yoon YJ; Lim MJ; Park CH
J Neurosci Res; 2015 Aug; 93(8):1267-78. PubMed ID: 25711470
[TBL] [Abstract][Full Text] [Related]
30. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
Perez-Lloret S; Rascol O
Expert Rev Neurother; 2016; 16(3):245-58. PubMed ID: 26849427
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
Cattaneo C; Jost WH; Bonizzoni E
J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
[TBL] [Abstract][Full Text] [Related]
32. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Alborghetti M; Nicoletti F
Curr Neuropharmacol; 2019; 17(9):861-873. PubMed ID: 30160213
[TBL] [Abstract][Full Text] [Related]
33. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
34. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease.
Müller T; Riederer P; Grünblatt E
Clin Neuropharmacol; 2017; 40(5):208-211. PubMed ID: 28682929
[TBL] [Abstract][Full Text] [Related]
35. Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.
Avila A; Caballol N; Martín-Baranera M; Gómez-Ruiz I; Balagué-Marmaña M; Planas-Ballvé A; Cardona X
Acta Neurol Scand; 2019 Jul; 140(1):23-31. PubMed ID: 30963543
[TBL] [Abstract][Full Text] [Related]
36. The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
Abbruzzese G; Barone P; Lopiano L; Stocchi F
Drug Des Devel Ther; 2021; 15():2507-2517. PubMed ID: 34140766
[TBL] [Abstract][Full Text] [Related]
37. Novel MAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinson's disease.
Unzeta M; Sanz E
Int Rev Neurobiol; 2011; 100():217-36. PubMed ID: 21971010
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
[TBL] [Abstract][Full Text] [Related]
39. Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies.
Wasan H; Singh D; Kh R
Brain Res Bull; 2021 Mar; 168():165-177. PubMed ID: 33387637
[TBL] [Abstract][Full Text] [Related]
40. Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.
Schapira AH
CNS Drugs; 2011 Dec; 25(12):1061-71. PubMed ID: 22133327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
